A favorable court ruling has allowed Sandoz Canada to launch the first generic version of Roche’s Esbriet to treat idiopathic pulmonary fibrosis.
Sandoz Canada has launched the first generic version of Roche’s Esbriet (pirfenidone) 267mg and 801mg tablets, following a favorable court ruling over the treatment of idiopathic pulmonary fibrosis.
Federal Court Judge Michael Manson had earlier ruled that claims of Canadian patents 2,667,654 and 2,709,997 asserted against Sandoz by...
As Endo and Mallinckrodt continue to work towards consummating the merger they announced earlier this year, the pair have revealed further organizational details of their combined generics and sterile injectables business, which is set to be spun off after the merger is complete.
The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.
Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.
Ahead of a bench trial beginning in February 2026, Lupin has become the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster by the end of the decade.
The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.
Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.
Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.
